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Abstract
Red blood cell (RBC) transfusion is a common intervention in intensive care unit (ICU) patients. Anemia is frequent
in this population and is associated with poor outcomes, especially in patients with ischemic heart disease.
Although blood transfusions are generally given to improve tissue oxygenation, they do not systematically increase
oxygen consumption and effects on oxygen delivery are not always very impressive. Blood transfusion may be
lifesaving in some circumstances, but many studies have reported increased morbidity and mortality in transfused
patients. This review focuses on some important aspects of RBC transfusion in the ICU, including physiologic
considerations, a brief description of serious infectious and noninfectious hazards of transfusion, and the effects of
RBC storage lesions. Emphasis is placed on the importance of personalizing blood transfusion according to
physiological endpoints rather than arbitrary thresholds.
Introduction
Red blood cell (RBC) transfusion is commonly required in
critically ill patients. Several recent, observational, multi-
center studies reported that approximately one third of
critically ill patients received a blood transfusion at one
time or another during their stay in the intensive care unit
(ICU) (Table 1). Because of the frequent use of this inter-
vention, it is important for the ICU physician to be aware
of recent developments in this continuously evolving field
of medicine. In this narrative review, we consider some
key aspects of transfusion medicine in the ICU, focusing
on aspects relevant to the critically ill patient, including
prevalence and reasons for blood transfusion, epidemiol-
ogy and etiology of anemia in these patients, pathophysio-
logical considerations on tolerance to anemia, and efficacy
of RBC transfusion. Safety concerns, including questions
of RBC storage and leukoreduction, are then discussed,
followed by a proposal for an integrated approach to
transfusion decisions and a discussion on economic
aspects and alternatives to blood transfusion.
Epidemiology of anemia and red blood cell
transfusion in the ICU
Anemia is common in ICU patients and appears early in
the ICU course [1]. In an observational, multicenter,
cohort study in Scotland, 25% of patients admitted to
the ICU had a hemoglobin level < 9 g/dl [2]. Similar
results were reported in the ABC study [3], in which
29% of patients had a hemoglobin concentration < 10 g/
dl on admission. Even in nonbleeding ICU patients,
hemoglobin levels tend to decrease early [3]. This
decrease is more pronounced in septic than in nonseptic
patients [4], at least in part because of their inflamma-
tory response; more frequent blood sampling may also
contribute.
Interestingly, anemia and the need to restore adequate
oxygen delivery (DO2) are the most common indications
for transfusion, rather than acute bleeding [3,5-10]. Ane-
mia in the critically ill patient is a multifactorial phe-
nomenon that has been compared to the so-called
“anemia of chronic illness” [11]. Apart from evident
causes of anemia, such as primary blood losses (e.g.,
trauma, surgery, gastrointestinal bleeding), multiple
other etiologies contribute to its pathophysiology and
often coexist in the same patient [11]. These include
blood losses related to minor procedures or phlebotomy,
and hemodilution secondary to fluid resuscitation. Some
studies have suggested that blood sampling may average
as much as 40 ml/day [3,4], but the amount of blood
required may decrease with technological developments
in analytic methods. Other mechanisms for anemia
include an inflammatory response with blunted erythro-
poietin (EPO) production, abnormalities in iron
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any medium, provided the original work is properly cited.Table 1 Multicenter observational studies of transfusion in general ICU patients
Author Year study was
conducted
Country/region No. of patients and
number of ICUs
Percentage
transfused in ICU
Pretransfusion
hemoglobin level
Mean no. of units
transfused in ICU
Mean age of
blood (days)
Hebert et al. [9] 1993 Canada 5,298 patients in 6 ICUs 25.0 Mean: 8.6 ± 1.3 g/dl NS NS
Vincent et al. [3] 1999 Western Europe 3,534 patients in 146 ICUs 37.0 Mean: 8.4 ± 1.3 g/dl 4.8 ± 5.2 16.2 ± 6.7
Rao et al. [6] 1999 UK 1,247 patients in 9 ICUs 53.0 Median: 8.5 (IQR: 7.9-9)
g/dl
6.75 (hemorrhage) and 4.25
(anemia)
NS
Corwin et al. [5] 2000 - 2001 USA 4,892 patients in 284 ICUs 44.0 Mean: 8.6 ± 1.7 g/dl 4.6 ± 4.9 21 ± 11.4
Walsh et al. [7] 2001 UK (Scotland) 1,023 patients in 10 ICUs 39.5 Median: 7.8 (7.3-8.5) g/dl Mean: 1.87 unit/ICU
admission
NS
French et al. [10] 2001 Australia and New
Zealand
1,808 patients in 18 ICUs 19.8 Median: 8.2
(range: 4.4-18.7) g/dl
Mean: 4.18 NS
Vincent et al. [34] 2002 Western and Eastern
Europe
3,147 patients in 198 ICUs 33.0 Median: 8.2 g/dl 5.0 ± 5.8 NS
Westbrook et al. [8] 2008 Australia and New
Zealand
5,128 patients in 47 ICUs 14.7 Mean: 7.7 g/dl Median: 2 (IQR: 1-4) Median: 14
(IQR: 9.5-21.5)
ICU intensive care unit; NS not specified; IQR interquartile range
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9metabolism, and altered proliferation and differentiation
of medullar erythroid precursors [11]. As a consequence,
RBC deformability is decreased [12], whereas RBC
adherence to the endothelium is increased, especially in
septic patients, potentially leading to microcirculatory
impairment and tissue hypoxia [13].
Tolerance to anemia in healthy subjects and in
the critically ill patient
Tolerance to anemia is highly dependent on the volume
status of the patient, physiological reserve, and the
dynamics of the anemia (for example, chronic, such as
the anemia of sepsis, versus acute, such as hemorrhagic
conditions). Normovolemic anemia is better tolerated
than anemia in hypovolemic states (e.g., acute bleeding
in trauma patients or surgery) in which cardiac output
acutely decreases. In healthy subjects submitted to nor-
movolemic hemodilution, cardiac output increases
because of decreased blood viscosity (especially relevant
in severe anemia) and increased adrenergic response,
allowing tachycardia and increased myocardial contracti-
lity. Other phenomena include blood flow redistribution
(to heart and brain) and an increased oxygen extraction
ratio (reflected by a decrease in mixed venous saturation
[SvO2]). These mechanisms allow healthy humans to
tolerate severe degrees of normovolemic anemia [14,15],
although side effects, such as arrhythmias or ST
changes, can be observed in extreme cases [16,17]. The
myocardium is the organ at risk in cases of acute ane-
mia in which both tachycardia and increased ventricle
contractility may increase myocardial oxygen demand.
Because myocardial oxygen extraction is already almost
maximal at rest, every increase in myocardial oxygen
demand must be accompanied by increased coronary
blood flow [18]. This can become problematic in
patients with stenotic coronary arteries especially when
tachycardia is present, which can decrease diastole-
dependent left ventricle perfusion.
Therefore, in critically ill patients, especially those
with heart failure or coronary artery disease (CAD), the
myocardium may not tolerate such low hemoglobin
levels [19]. In acute myocardial infarction, anemia may
worsen myocardial ischemia, generate arrhythmias, and
potentially increase infarct size [20]. In patients with
acute coronary syndrome or heart failure, anemia
increases morbidity and mortality [21,22]. For these rea-
sons, patients with cardiac problems should be managed
with a more liberal approach to transfusion than other
patients [23,24].
Purpose and efficacy of blood transfusion
The primary purpose of blood transfusion is to
increase DO2, which is determined by cardiac output
and arterial content of oxygen, the latter being
dependent on the hemoglobin level. Hence, blood
transfusions can, theoretically at least, limit tissue
hypoxia [13,25,26]. But does this really happen in clini-
cal practice? It is obvious that RBC transfusions can be
lifesaving in situations of acute severe anemia or in
bleeding patients in whom RBC administration can
increase both oxygen arterial content and cardiac out-
put. However, in the absence of bleeding, the increase
in hemoglobin concentration could very well be offset
by a decrease in cardiac output because of the increase
in blood viscosity associated with a decreased sympa-
thetic response [27,28]. DO2 has been shown to
increase following RBC transfusion in numerous stu-
dies [26], but not in all [29].
The effects of RBC transfusion on the relationship
between DO2 and oxygen uptake (VO2) are even more
difficult to predict. Some studies reported that VO2
increased following RBC transfusion, whereas others did
not [26], and variable effects have been reported on tis-
sue perfusion as assessed by gastric mucosal pH or
near-infrared spectroscopy (NIRS) [30]. The reasons for
these contradictory results lie primarily in the degree of
severity of hypoxia preceding the RBC transfusion [31],
which influences the dependency of VO2 on DO2. Meth-
odological problems (imprecision in determination of
VO2, assessment of global VO2 instead of regional VO2,
poor correlation between systemic oxygenation para-
meters, and oxygenation in the microcirculation [13])
also may contribute to these discrepancies [31].
Safety concerns of blood transfusions
Impact on outcome
Red blood cell transfusions have been associated with
worse outcomes in several populations of patients,
including critically ill patients. In a recent systematic
review of 45 observational studies reporting the
impact of transfusions on patient outcome (mortality,
infections, acute respiratory distress syndrome
[ARDS]) in populations of trauma, general surgery,
orthopedic surgery, acute coronary syndrome, and
ICU patients, Marik and Corwin [32] identified RBC
transfusion as an independent predictor of death
(pooled odds ratio (OR) from 12 studies, 1.7; 95%
confidence interval (CI), 1.4-1.9), infectious complica-
tions (pooled OR from 9 studies, 1.8; 95% CI, 1.5-2.2),
and ARDS (pooled OR from 6 studies, 2.5; 95% CI,
1.6-3.3). In ICU patients, the three studies included in
the review (ABC study [3], CRIT study [5], and a
study by Gong et al. [33]) consistently showed a sta-
tistically significant association of RBC transfusion
with mortality.
On the other hand, analysis of data from a multicen-
ter, prospective, observational study of 3,147 patients in
198 European ICUs (the SOAP study) indicated that
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m o r t a l i t yb ym u l t i v a r i a t ea n a lysis or propensity match-
ing [34]. In contrast, an extended Cox proportional
hazard analysis showed that patients who received a
transfusion in fact had a better survival, all factors being
otherwise equal. An increased rate of transfused leukor-
educed RBCs reported in this study (in which 76% of
centers routinely used leukoreduced RBCs) could per-
haps account for the differences between the earlier
ABC study [3] (in which 46% of centers used leukode-
pleted blood most of the time) and the SOAP study
[34]. It also is possible that transfusion thresholds have
become so low that the benefits of blood transfusion
outweigh the risks.
In patients with acute coronary syndrome, several stu-
dies have shown poorer outcomes, including increased
mortality, in transfused groups compared with nontrans-
fused patients after adjustment for potential confounders
[21,35-37]; similar findings have been reported in
patients who undergo percutaneous coronary interven-
tions (PCI) [38]. However, although still controversial,
RBC transfusions may be useful in subgroups of elderly
patients with acute myocardial infarction [39] or
patients with ST elevation myocardial infarction
(STEMI) [21].
Patients who undergo cardiac surgery seem to have
worse outcomes when transfused, including higher mor-
tality [40,41], increased occurrence of postoperative
infections [41,42], increased time on mechanical ventila-
tion [40,43], and higher incidence of postoperative acute
kidney injury [41,44].
Other studies have reported that trauma patients
[45,46], including those with burns [47], may have
increased mortality rates associated with receiving blood
transfusions. In contrast, RBC transfusion has been
reported to be associated with improved outcomes in
patients with traumatic brain injury or subarachnoid
hemorrhage [48,49]. In the early resuscitation of patients
with severe sepsis, implementation of a therapeutic pro-
tocol that included RBC transfusion to obtain a hemato-
crit > 30% was associated with a significant reduction in
hospital mortality [50].
These results should be interpreted with caution,
because most of these data come from observational,
retrospective studies, which are subject to numerous
biases and sometimes control poorly for confounders,
despite the use of various statistical tools, such as logis-
tic regression [51]. It is clear that analyses should not
include only admission data. For example, in a well-
defined patient population, such as after cardiac surgery,
patients who develop gastrointestinal bleeding and
require a blood transfusion have a worse prognosis,
which is not necessarily the result of the blood transfu-
sion. It is of paramount importance that all risks factors
are taken into account. Ruttinger et al. [52] illustrated
this point very well. In a series of more than 3,000 sur-
gical patients, these authors showed by using a limited
multivariable analysis that transfusions were associated
with a worse outcome, but a more complete analysis
cancelled out this statistical observation.
Noninfectious serious hazards of transfusions
The reasons for the apparent worse outcome of trans-
fused compared with nontransfused critically ill patients
may be found in several detrimental effects of transfused
blood, globally referred to under the acronym “Non-
Infectious Serious Hazards Of Transfusion” or NISHOT
(Table 2) [53]. These include, among others, deleterious
effects on the immune system (transfusion-related
immunomodulation or “TRIM”) or on the cardiopul-
monary system, e.g., transfusion-related acute lung
injury ("TRALI”) [54] or transfusion-associated circula-
tory overload ("TACO”); the latter is currently the lead-
ing reported cause of transfusion-associated mortality
[55]. These effects may be enhanced by pathologic con-
ditions (e.g., sepsis) in which the microcirculation is
impaired [56] and/or when the RBCs have been stored
for some time.
Question of RBC storage
During storage, RBCs undergo a series of biological and
biochemical changes collectively referred to as “the sto-
rage lesion” [57]. This includes intracellular changes
(progressive depletion of 2,3-diphosphoglycerate [2,3-
DPG] with increased affinity of hemoglobin for oxygen,
depletion of ATP), membrane changes (membrane vesi-
culation, morphological changes eventually leading to
irreversibly deformed spheroechinocytes, lipid peroxida-
tion and increased expression of phosphatidylserine,
decreased deformability), and changes in the storage
medium (decreased pH, increased potassium, release of
proinflammatory cytokines). These stored RBCs also
have an increased tendency to adhere to endothelium
and could promote vasoconstriction; the stored RBCs
act as a “sink” for nitric oxide [58]. Some animal studies
[13] have shown deleterious effects of old RBCs on the
microcirculation (potentially leading to tissue hypoxia
and organ dysfunction). A human study found an
inverse correlation between the age of transfused RBCs
and maximal change in gastric mucosal pH, but these
findings were challenged in subsequent studies [59-61].
The clinical consequences of storage lesions are still
not clear. A recent review of the literature [57] identi-
fied 24 studies that address the effects of RBC length of
storage on clinical (mortality, infections, length of stay,
length of mechanical ventilation) or physiological
(microcirculation, gastric mucosal pH) endpoints. Some
studies found associations between the age of transfused
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Overall, no clear detrimental effect of RBC age could be
identified; however, definitive conclusions are difficult to
obtain because of numerous statistical limitations and
biases inherent to the study designs [51,62]. Several,
large, randomized, controlled trials in adult ICU and
cardiac surgery patients are currently ongoing to address
the clinical relevance of RBC storage. In the multicenter,
double-blind prospective ABLE (Age of Blood Evalua-
tion) study [63], adult patients admitted to the ICU are
randomly assigned to receive leukoreduced RBCs stored
for less than 7 days or issued according to standard pro-
cedure (expected average storage time of 19 days). The
primary endpoint of this study is 90-day all-cause mor-
tality. The target number of patients is 2,510 (for an
expected improvement in primary endpoint greater than
5%) with an anticipated completion date by April 2013.
T h eR e dC e l lS t o r a g eD u r a t ion Study (RECESS) is a
multicenter, randomized study in patients (age 12 years
and older) who undergo complex cardiac surgery and
are likely to require RBC transfusion [64]. Patients who
need transfusion are randomized to receive RBCs stored
for ≤ 10 days or ≥ 21 days. The primary endpoint of
this study is the change in the Multiple Organ Dysfunc-
tion Score (MODS) from baseline to day 7, with second-
ary outcomes including all-cause 28-day mortality. The
target number of patients is 1,832, and the anticipated
completion date is September 2013.
The results of these trials, especially if older blood
appears to be harmful, could have important logistic
implications for blood banks [65,66].
Question of leukoreduction
Many of the adverse effects associated with the transfu-
sion of allogeneic RBCs have been shown to be related
to the infusion of white blood cells (WBCs) present in
the blood product. Leukoreduction is a process in which
WBCs are reduced in number through centrifugation or
filtration [67]. This process allows removal of approxi-
mately 99.995% of WBCs, but several thousand leuko-
cytes (0.005% of a 500 ml blood unit) may still be
present in the processed blood [67]; hence, the word
“leukoreduction” is better than “deleukocytation.” The
beneficial effects of this process include decreased
Table 2 Selected infectious and non-infectious hazards of RBC transfusion in the ICU environment
Estimated frequency (event/no. of
transfusions)*
Comment
Infectious transmission [89,90]
HIV 1/2.3 10
6
HBV 1/350000
HCV 1/1.8 10
6
HTLV 1/2 1/2 10
6
Bacterial contamination 1/14,000 to 1/28,000 GNB such as Y. Enterocolitica mostly encountered
Noninfectious complications
Immune-mediated [53,89]
Acute hemolytic transfusion
reactions
1/10,000 to 1/50,000 Most frequently due to IgM, sometimes IgG
Febrile nonhemolytic
transfusion reactions
1/500 Reduced incidence with prestorage leukoreduction
Anaphylactic reactions 1/20,000 to 1/50,000 May be associated with IgA deficiency
Transfusion-related acute
lung injury (TRALI)
Highly variable (e.g., 1/29,000 [91], 1/46,700 [92],
1/173,000 [93] units transfused)
Must be differentiated from TACO
Posttransfusion purpura 1/143,000 Rare; occurs 5-10 days after transfusion
Transfusion-associated graft
versus host disease
Rare (prevention by irradiation
of blood products)
Mostly in immunocompromised hosts, poor prognosis
Nonimmune-mediated [89,94]
Incorrect blood component
transfused (IBCT)
9.7/100,000 components Remains frequent despite prevention strategies; must be
differentiated from near-miss transfusion
Transfusion-associated
circulatory overload (TACO)
Up to 1% of transfusions Major cause of transfusion-related death
Hyperkalemia Mainly after transfusion in newborns
Hypocalcemia - hypothermia
Mainly after massive transfusion
Dilutional coagulopathy/
thrombocytopenia Mainly after massive transfusion
HIV human immunodeficiency virus; HBV hepatitis B virus; HCV hepatitis C virus; HTLV human T lymphotropic virus; GNB Gram-negative bacteria
*Frequencies may vary among studies and are only indicative
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transmission of certain pathogens, such as Epstein-Barr
virus (EBV) or cytomegalovirus (CMV), parasites and
prions [67], and possibly decreased lung injury, such as
TRALI. Moreover, prestorage leukoreduction, in which
WBC removal occurs before RBC storage, avoids the
need for a leukodepletion filter during transfusion [67]
(but a 170-200-μm filter still needs to be incorporated
into the intravenous blood line).
In several studies, prestorage leukoreduction decreased
RBC storage lesions, with fewer immunomodulating
properties [68] and less adhesion of stored RBCs to the
endothelium [69]. A clinical benefit of leukoreduction is
still somewhat controversial, particularly in the critically
ill patient where no randomized, controlled trial has
been performed [70]. In a before-after study of 14,786
patients who underwent cardiac surgery, repair of hip
fracture, or who required intensive care after surgery,
there was a 1% decrease in mortality rate associated
with the implementation of universal leukoreduction
[71]. In a recent meta-analysis of nine RCTs involving
3,093 surgical patients, the use of leukoreduction signifi-
cantly reduced the odds of postoperative infection (sum-
m a r yO R ,0 . 5 2 2 ;9 5 %C I ,0 . 3 3 2 - 0 . 8 2 1 ;p = 0.005) [72].
This observation had been suggested in a previous
meta-analysis [73] but has been challenged by another
recent meta-analysis [74]. Nevertheless, leukoreduction
makes sense, and many countries have adopted it as
routine, even though costs are elevated. In Europe, at
the time of the SOAP study in 2002, 76% of centers
reported using leukodepleted blood routinely [34],
whereas an earlier study performed in the same coun-
tries reported lower rates [3].
The decision to transfuse
Classically, the decision to transfuse is driven by arbi-
trary “triggers” (hemoglobin level) rather than clinical or
physiologic findings. Data from the CRIT study [5], in
which there was little evidence that age or comorbidities
significantly influenced transfusion practice, tend to sup-
port this view.
Current recommendations for RBC transfusion [75,76]
are mainly based on the famous “TRICC” (Transfusion
Requirements In Critical Care) trial in which patients
assigned to a restrictive transfusion strategy (transfusion
if hemoglobin level < 7 g/dl) had similar 30-day mortal-
ity rates (and even lower mortality in subgroups with
APACHE II < 20 and patients younger than age 55
years) than patients transfused according to a more lib-
eral strategy (transfusion if hemoglobin level < 10 g/dl)
[77]. In cardiac surgery patients, the recent randomized,
monocenter “TRACS” (Transfusion Requirements after
Cardiac Surgery) trial, which compared a restrictive to a
liberal strategy (transfusion when hematocrit < 24% or
< 30%, respectively), reported no difference in the pri-
mary endpoint (composite of 30-day mortality and mor-
bidity [cardiogenic shock, ARDS, acute kidney injury])
between the groups [78].
However, it is quite clear there is no “magic” hemo-
globin or hematocrit trigger, and for the same level of
hemoglobin, some patients will do well, whereas others
will not. Thus, the decision to transfuse a patient should
be individualized, taking into account several factors,
including signs and symptoms of tissue hypoxia (angina
pectoris, cognitive dysfunction diagnosed by neuropsy-
chological tests, or increased P300 latencies [79-81]),
increased blood lactate levels [82], or electrocardio-
graphic changes suggestive of myocardial ischemia.
Indirect measures of oxygenation, such as a decreased
SvO2 or central venous oxygen saturation (ScvO2), also
may be considered [82]. For example, in a study of early
goal-directed therapy in patients with severe sepsis or
septic shock admitted to an emergency department, a
decrease in ScvO2 < 70% initiated a therapeutic inter-
vention, including fluid resuscitation, inotropes, vaso-
pressors, and RBC transfusion to increase hematocrit to
> 30% [50]. Use of a decreased ratio of cardiac index to
oxygen extraction (CI/EO2 ratio) may be better, because
this parameter also reflects the cardiac response to ane-
mia [83].
Economic aspects of blood transfusion
The costs of blood transfusion are particularly complex to
assess because of the many factors that have to be taken
into consideration (blood collection and screening for
pathogens; blood component processing, including leukor-
eduction, storage, transport to the transfusion facility;
administration of blood to the patient; management of
potential short- and long-term transfusion-related side
effects) [84]. The subtype of the blood unit also may play a
role because some products, such as CMV-negative or
autologous units, are costlier than classical allogeneic
RBCs. Consequently, studies in this field have given extre-
mely varied results, which are not easily comparable.
Evidence has shown increased costs of RBC transfusion
over time [85], related to various factors, including (but
not limited to) use of leukoreduction and more sophisti-
cated methods for pathogen detection, such as nucleic
acid testing (NAT) [84]. For example, a study in Canada
evaluated the mean societal cost of one allogeneic RBC
unit at 264.81 US$, twice the cost estimated 7 years ear-
lier [86]. Generally, these reported values are probably
underestimated, and some have calculated that the cost
of blood to society could in fact be twofold higher [84].
Alternatives to blood transfusion
Because of limited availability, costs and safety concerns
related to blood transfusion, several strategies to reduce
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increasing transfusion trigger thresholds. These include
approaches to reduce blood losses, for example use of
antifibrinolytic agents, such as tranexamic acid or epsi-
lon-aminocaproic acid (EACA) and techniques of cell sal-
vage during surgery; also, the use of small volume sample
tubes can limit the blood losses related to sampling for
laboratory studies. In a meta-analysis of 9 randomized
controlled trials [87], subcutaneous administration of
recombinant erythropoietin (EPO) in critically ill patients
was shown to be associated with decreased transfusion
rates, but this was not associated with improved mortality
(except possibly in a subgroup of trauma patients [88]).
Concerns also have been raised about potentially
increased rates of deep vein thrombosis [88]. The devel-
opment of artificial oxygen carriers is under investigation,
but these have their own problems [89]. Further research
is needed to improve these alternative strategies.
Conclusions
RBC transfusion can be lifesaving. During the past two
decades, however, safety concerns have emerged, with
suggestions that morbidity and mortality may be
increased in patients who receive blood transfusions.
Therefore, the decision to transfuse should be individua-
lized, based on a rational approach and taking into
account physiologic variables in addition to the hemo-
globin value. This strategy, along with the use of alter-
natives whenever possible to limit bleeding, should limit
unnecessary exposure to RBCs.
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